CD274 and lung adenocarcinoma: Moreover, patients with PDL1-positive lung adenocarcinoma are more likely to benefit from immunotherapy than those with PDL1-negative lung adenocarcinoma (Gridelli et al., 2018; Dafni et al., 2019), suggesting that PDL1 expression plays a major role in the pathogenesis of lung adenocarcinoma.